Company intelligence / Profile preview

Apricity

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Early-stage company developing transporter-targeted platinum drugs and other therapeutics, with multiple NIH/SBIR grants totaling over $1M for research

Modalities: Small moleculeSmall molecule
Industry: Non-Academic Healthcare

Drug pipeline

1 asset

Transporter-targeted platinum drug

Pre-clinical

Indications: Glioblastoma, Neuroblastoma, Pediatric tumors

Beyond the preview

Go deeper on Apricity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apricity.

Explore the full profile